Beamtree Holdings Ltd (AU:BMT)
ASX:BMT
Top Page
Beamtree Holdings Ltd
(Sydney:BMT)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.16
▼(-27.27% Downside)
Action:ReiteratedDate:02/21/26
The score is primarily driven down by weak financial performance (loss-making operations, negative revenue growth, and cash flow strain) and bearish technical momentum (price below key moving averages with negative MACD). Valuation is only modestly supportive because the negative P/E reflects current losses and dividend yield is unavailable.
Positive Factors
High gross margin
An observed 100% gross profit margin indicates the core product has minimal direct costs, implying a highly scalable software/data business. If revenue growth resumes, this margin profile can translate to strong operating leverage and long-term margin expansion once fixed costs are absorbed.
Negative Factors
Negative operating profitability
Negative EBIT and EBITDA margins show the company remains unprofitable at the operating level. Persistent operating losses erode equity and constrain reinvestment; without sustained revenue improvement or material cost reductions, recovering durable profitability will be difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margin
An observed 100% gross profit margin indicates the core product has minimal direct costs, implying a highly scalable software/data business. If revenue growth resumes, this margin profile can translate to strong operating leverage and long-term margin expansion once fixed costs are absorbed.
Read all positive factors
Beamtree Holdings Ltd (BMT) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$43.60M
Dividend YieldN/A
Average Volume (3M)122.51K
Price to Earnings (P/E)―
Beta (1Y)0.95
Revenue Growth3.61%
EPS Growth-17.03%
CountryAU
Employees97
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.01
Shares Outstanding290,643,220
10 Day Avg. Volume152,204
30 Day Avg. Volume122,509
Financial Highlights & Ratios
PEG Ratio-0.66
Price to Book (P/B)1.72
Price to Sales (P/S)2.53
P/FCF Ratio-39.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.30Price Target Upside36.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.01
Revenue Forecast (FY)AU$31.40M
Beamtree Holdings Ltd Business Overview & Revenue Model
Company Description
Beamtree Holdings Limited develops and commercializes clinical decision support (CDS) systems to healthcare industry in Australia and internationally. The company offers RippleDown Expert, a CDS system that provides real-time patient monitoring an...
How the Company Makes Money
Beamtree Holdings Ltd generates revenue primarily through the sale of its software solutions and data analytics services to healthcare providers, including hospitals, clinics, and mental health organizations. The company adopts a subscription-base...
Beamtree Holdings Ltd Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
55
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 28.90M | 28.60M | 27.60M | 22.77M | 16.55M | 8.39M |
| Gross Profit | 1.66M | 28.60M | 4.89M | 2.14M | -202.00K | 2.77M |
| EBITDA | -4.74M | -808.00K | -331.00K | -1.26M | -2.28M | 1.02M |
| Net Income | -5.78M | -6.16M | -5.11M | -6.91M | -4.45M | -383.62K |
Balance Sheet | ||||||
| Total Assets | 53.26M | 54.29M | 59.65M | 62.53M | 63.91M | 47.05M |
| Cash, Cash Equivalents and Short-Term Investments | 2.94M | 4.78M | 5.04M | 8.81M | 6.35M | 14.12M |
| Total Debt | 3.65M | 3.26M | 1.66M | 755.00K | 1.12M | 799.36K |
| Total Liabilities | 13.76M | 12.36M | 12.52M | 15.31M | 15.33M | 4.96M |
| Stockholders Equity | 39.51M | 41.93M | 47.14M | 47.22M | 48.58M | 42.09M |
Cash Flow | ||||||
| Free Cash Flow | 906.00K | -1.84M | -4.51M | -1.88M | -4.83M | -2.64M |
| Operating Cash Flow | 1.08M | 609.00K | -492.00K | 768.00K | -2.32M | 240.65K |
| Investing Cash Flow | -3.37M | -2.45M | -4.02M | -2.65M | -5.16M | -2.98M |
| Financing Cash Flow | 1.54M | 1.58M | 749.00K | 4.34M | -286.00K | 12.65M |
Beamtree Holdings Ltd Technical Analysis
Positive
0.22
Price Trends
0.16
Negative
0.18
Negative
0.21
Negative
Market Momentum
>-0.01
Negative
49.39
Neutral
75.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BMT, the sentiment is Positive. The current price of 0.22 is above the 20-day moving average (MA) of 0.15, above the 50-day MA of 0.16, and above the 200-day MA of 0.21, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 49.39 is Neutral, neither overbought nor oversold. The STOCH value of 75.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:BMT.
Beamtree Holdings Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | AU$134.30M | 26.51 | 4.37% | ― | 10.06% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$72.85M | -6.28 | -23.86% | ― | 15.99% | 22.05% | |
47 Neutral | AU$19.56M | 3.95 | 7.57% | ― | 28.91% | -1050.00% | |
44 Neutral | AU$43.60M | -5.70 | -14.19% | ― | 3.61% | -17.03% | |
43 Neutral | AU$31.35M | -3.13 | -1009.84% | ― | 25.98% | 22.10% |
* Healthcare Sector Average
AU:BMT
Beamtree Holdings Ltd
0.15
-0.07
-31.82%
AU:M7T
Mach7 Technologies
0.31
<0.01
1.64%
AU:RHT
Resonance Health Ltd
0.04
0.00
0.00%
AU:ALC
Alcidion Group Limited
0.10
0.02
25.00%
AU:PCK
PainChek Ltd
0.15
-0.18
-54.41%
Beamtree Holdings Ltd Corporate Events
Beamtree Appoints Martin Bowles to Board Without Equity Stake
Mar 9, 2026
Beamtree Holdings Limited has announced the appointment of Martin Bowles as a director, effective 2 March 2026, and lodged the required initial director’s interest notice with the ASX. The filing confirms that Bowles currently holds no relev...
Mirrabooka Exits Substantial Holder Position in Beamtree After Corrected Filing
Mar 4, 2026
Mirrabooka Investments Limited has notified Beamtree Holdings Limited that it has ceased to be a substantial holder in the company as of 3 March 2026. The change was communicated through a corrected statutory notice, replacing an earlier version l...
Mirrabooka exits substantial holding in Beamtree Holdings
Mar 4, 2026
Mirrabooka Investments Limited has notified Beamtree Holdings Limited that it has ceased to be a substantial shareholder as of 3 March 2026, in line with Australian disclosure rules for significant holdings. The move follows a series of trades whe...
Beamtree Reshapes Board and Pay Structure as Strategic Review Begins
Mar 1, 2026
Beamtree Holdings has reshaped its governance structure as it undertakes a strategic review aimed at unlocking shareholder value, with Chair Emma Gray stepping into a time-limited Executive Chair role to oversee the process while CEO Marek Stepnia...
Beamtree Sets Date for 1H FY26 Results and Investor Webinar
Jan 28, 2026
Beamtree Holdings Limited has announced that it will release its half-year results for the first half of FY26 on 25 February 2026 and will host an investor webinar the same day at 9:00am AEST to discuss the performance. The scheduled update unders...
Beamtree Seeks ASX Quotation for New Shares Issued Under Employee Plan
Jan 12, 2026
Beamtree Holdings Limited has applied for quotation on the ASX of 46,045 new fully paid ordinary shares issued on 13 January 2026 under its Employee Incentive Plan, pursuant to salary contribution arrangements. The modest equity issuance reflects ...
Beamtree Issues 1 Million Unquoted Performance Rights Under Employee Incentive Plan
Jan 12, 2026
Beamtree Holdings Limited has issued 1,000,000 unquoted performance rights under its employee incentive scheme, with the new securities designated under ASX code BMTAC and issued on 9 January 2026. The performance rights are subject to transfer re...
Beamtree Issues 700,000 Unquoted Performance Rights Under Employee Incentive Scheme
Dec 19, 2025
Beamtree Holdings Limited has notified the market of the issue of 700,000 unquoted performance rights under its employee incentive scheme, with an issue date of 14 November 2025. The new equity allocation forms part of Beamtree’s strategy to...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.